ELVN

Enliven is a pre-revenue, clinical-stage biopharma whose entire equity story now rides on ELVN-001, a BCR-ABL inhibitor heading into a pivotal trial. Management explicitly states they are 'exploring strategic alternatives for the ELVN-002 program and are no longer pursuing its development,' concentrating risk on a single asset — the Risk Factors flag this directly ('We are substantially dependent on ELVN-001'). The FY2025 P&L shows the expected biotech profile: zero revenue, a $104M net loss (worsening 16.5% YoY), $85.9M R&D, and an accumulated deficit of $347M. Operating cash burn was -$70.3M for the year. This is not a fundamentals story in the traditional sense; it is an option on clinical readouts.

The balance sheet is the reason this is a hold rather than an avoid. Total assets jumped 46.2% to $476M against just $16.6M of liabilities (L/E of 0.04x), funded by the June 2025 public offering ($230M gross) plus $40M from the ATM Sales Agreement. Management discloses $462.6M of cash, equivalents and marketable securities at year-end and guides to runway 'sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months' from the 10-K filing — at the ~$70M annual burn rate, the cash position implies materially longer runway than the conservative 12-month statutory guidance, likely enough to reach pivotal data without an emergency raise. The 22% YoY share-count increase (to 59.8M) is the price already paid for that optionality.